Browse by popular tags
abvd act acute lymphoblastic leukaemia acute myelogenous leukemia (aml) acute myeloid leukaemia ade admire adoptive cellular therapy after 2 prior treatments alemtuzumab all allogeneic allogeneic stem cell transplant aml aml 17 angioimmunoblastic lymphoma antiviral therapy arctic autologous stem cell transplant autologous transplant azacitidine b-cell b-cell chronic lymphocytic leukaemia bexarotene blood cancers blood transfusions bone marrow bortezomib campath
NHS Logo
The Clinical research facility is part of the NIHR and is funded by the Department of Health
Eradication of Minimal Residual Disease (MRD) in
patients with Chronic Lymphocytic Leukaemia (CLL)
with Alemtuzumab: A Phase II Study
A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia
Genetic study of B-cell chronic lymphocytic leukaemia and other lymphoproliferative disease.